Observational studyMedicine2026
Tobacco-attributable burden of alzheimer's disease and other dementias in China and ASEAN: Temporal trends and projections - an observational study based on GBD 2021.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to systematically analyze the disease burden of Alzheimer's disease and other dementias (ADOD) attributed to tobacco in China and ASEAN countries from 1990 to 2021, and predict the disease burden in the next ten years to characterize the disparities in disease burden between the 2 sides, and to conduct a preliminary exploration of factors that may be associated with these disparities. Data on ADOD deaths, mortality, DALYs and DALY rates attributed to tobacco in China and ASEAN countries were extracted from GBD 2021, and the trend of disease burden was analyzed using Joinpoint regression model. R software was used for data analysis and visualization, and Joinpoint regression model was used to calculate the APC of each indicator; the disease burden attributable to tobacco in China and ASEAN countries was analyzed through the SDI; and the ARIMA was used to predict ADOD from 2022 to 2035. In China, the number of ADOD deaths (1990: 8126.47, 95% CI: 1822.19-22,577.84), mortality rate, DALYs, and DALY rate attributable to tobacco all exhibited significant and sustained upward trends from 1990 to 2021, and consistently exceeded the corresponding levels in the other ten ASEAN countries. The APC for mortality and DALY rates showed a significant increase in China and most ASEAN countries, with particularly rapid increases in mortality in China, Thailand, Cambodia, and Indonesia. Correspondingly, the DALY rate rose in most countries, indicating a growing overall disease burden. An exception was Myanmar, where the burden decreased. The burden of tobacco-attributable ADOD was consistently higher among males than females in all countries. Analysis based on SDI revealed a lower and more stable disease burden in high-SDI areas, whereas medium- and low-SDI countries demonstrated an upward trend. ARIMA model projections for 2022-2035 suggest that while mortality trends are diverse, an increasing trend is anticipated in most countries. The disease burden of ADOD attributable to tobacco use has continued to rise in China and ASEAN countries. This trend suggests a potential role for tobacco control in the prevention of ADOD, and also points to the value of strengthening tobacco regulation and paying early attention to cognitive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.